Quest Diagnostics Incorporated beat EPS estimates 100% of the time across 16 reported quarters (16 beats, 0 misses), averaging +4.1% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $2.81 | $3.12 | +11.0% | Beat | Q2 FY26 call |
| Q1 FY26 | $2.37 | $2.50 | +5.5% | Beat | Q1 FY26 call |
| Q3 FY25 | $2.51 | $2.60 | +3.6% | Beat | |
| Q2 FY25 | $2.57 | $2.62 | +1.9% | Beat | |
| Q1 FY25 | $2.15 | $2.21 | +2.8% | Beat | Q1 FY25 call |
| Q4 FY24 | $2.19 | $2.23 | +1.8% | Beat | |
| Q3 FY24 | $2.26 | $2.30 | +1.8% | Beat | |
| Q2 FY24 | $2.31 | $2.35 | +1.7% | Beat | Q2 FY24 call |
| Q1 FY24 | $1.86 | $2.04 | +9.7% | Beat | |
| Q4 FY23 | $2.14 | $2.15 | +0.5% | Beat | |
| Q3 FY23 | $2.19 | $2.22 | +1.4% | Beat | |
| Q2 FY23 | $2.23 | $2.30 | +3.1% | Beat |
Back to DGX overview · DGX holders · DGX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.